Linda Stein Gold Selected Research

calcipotriene (calcipotriol)

6/2022	Clinical, patient and estimated cost benefits of proactive management versus reactive management with calcipotriol/betamethasone dipropionate foam for the treatment of plaque psoriasis in Finland.
8/2021	Calcipotriene Plus Betamethasone Dipropionate Foam for Mild Psoriasis: Pooled Results from Three Randomized Trials.
4/2021	A Phase 3, Randomized Trial Demonstrating the Improved Efficacy and Patient Acceptability of Fixed Dose Calcipotriene and Betamethasone Dipropionate Cream.
11/2020	PSO-LONG: Design of a Novel, 12-Month Clinical Trial of Topical, Proactive Maintenance with Twice-Weekly Cal/BD Foam in Psoriasis.
8/2020	Fixed Combination Calcipotriene and Betamethasone Dipropionate (Cal/BD) Foam for Beyond-Mild Psoriasis: A Possible Alternative to Systemic Medication.
2/2019	The Clinical Relevance and Therapeutic Benefit of Established Active Ingredients Incorporated into Advanced Foam Vehicles: Vehicle Characteristics Can Influence and Improve Patient Outcomes
6/2018	Greater improvement in quality of life outcomes in patients using fixed-combination calcipotriol plus betamethasone dipropionate aerosol foam versus gel: results from the PSO-ABLE study.
12/2016	Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam is Effective, Independent of Body Mass Index and the Extent and Severity of Psoriasis.
8/2016	The Aerosol Foam Formulation of the Fixed Combination Calcipotriene Plus Betamethasone Dipropionate Improves the Health-Related Quality of Life in Patients With Psoriasis Vulgaris: Results from the Randomized PSO-FAST Study.
8/2016	Aerosol Foam Formulation of Fixed Combination Calcipotriene Plus Betamethasone Dipropionate is Highly Efficacious in Patients With Psoriasis Vulgaris: Pooled Data From Three Randomized Controlled Studies.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Linda Stein Gold Research Topics

Disease

44	Psoriasis (Pustulosis Palmaris et Plantaris) 10/2022 - 01/2007
31	Acne Vulgaris 06/2022 - 02/2012
9	Rosacea (Acne Rosacea) 04/2021 - 11/2014
7	Erythema 01/2020 - 03/2018
5	Headache (Headaches) 01/2022 - 08/2017
4	Nausea 01/2022 - 08/2017
4	Respiratory Tract Infections (Respiratory Tract Infection) 01/2022 - 08/2017
4	Diarrhea 01/2022 - 08/2017
4	Pruritus (Itching) 12/2021 - 08/2019
3	Nasopharyngitis 01/2022 - 02/2018
3	Atopic Dermatitis (Atopic Eczema) 04/2021 - 03/2021
3	Onychomycosis (Tinea Unguium) 09/2020 - 09/2014
3	Vomiting 07/2020 - 08/2017
2	Chronic Disease (Chronic Diseases) 01/2022 - 08/2018
2	Atrophy 12/2018 - 12/2018
2	Actinic Keratosis 11/2017 - 06/2013
1	Hypertriglyceridemia 01/2022
1	Oral Candidiasis (Thrush) 01/2022
1	Hyperpigmentation 01/2022
1	Pigmentation Disorders (Ito Syndrome) 01/2022
1	Melanosis (Freckles) 01/2022
1	Folliculitis (Sycosis) 12/2021
1	Contact Dermatitis (Eczema, Contact) 12/2021
1	Eczema 03/2021
1	Cicatrix (Scar) 03/2019
1	Virus Diseases (Viral Diseases) 01/2012
1	Hepatitis B 01/2012

Drug/Important Bio-Agent (IBA)

16	tazarotene (Tazorac)FDA Link 06/2022 - 01/2013
16	Immunoglobulin A (IgA)IBA 06/2021 - 12/2015
13	halobetasol (ulobetasol)FDA LinkGeneric 06/2022 - 07/2018
12	betamethasone-17,21-dipropionate (betamethasone dipropionate)FDA LinkGeneric 06/2022 - 01/2007
12	calcipotriene (calcipotriol)FDA LinkGeneric 06/2022 - 01/2007
10	Adapalene (Differin)FDA LinkGeneric 01/2022 - 02/2012
9	RetinoidsIBA 06/2022 - 01/2013
9	Benzoyl Peroxide FDA LinkGeneric 01/2022 - 06/2013
6	AerosolsIBA 08/2020 - 12/2015
5	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA 10/2022 - 03/2021
5	tapinarofIBA 10/2022 - 03/2021
5	Prostaglandins AIBA 12/2021 - 12/2013
5	Ivermectin (Mectizan)FDA Link 06/2020 - 11/2014
4	Adrenal Cortex Hormones (Corticosteroids)IBA 06/2022 - 12/2013
4	Isotretinoin (Accutane)FDA LinkGeneric 01/2022 - 03/2018
4	apremilastIBA 01/2022 - 08/2017
4	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 03/2015
4	Tretinoin (Retinoic Acid)FDA LinkGeneric 05/2021 - 11/2017
4	SteroidsIBA 02/2020 - 03/2016
3	Therapeutic UsesIBA 06/2022 - 07/2018
3	clindamycin phosphate (Clindets)FDA LinkGeneric 01/2022 - 09/2015
3	Ointments (Pastes)IBA 01/2022 - 01/2007
3	SolutionsIBA 09/2020 - 09/2014
3	efinaconazoleIBA 09/2020 - 09/2014
3	Oxymetazoline FDA Link 06/2020 - 03/2018
2	Tetracycline (Achromycin)FDA LinkGeneric 01/2022 - 06/2021
2	sarecyclineIBA 01/2022 - 06/2021
2	trifaroteneIBA 05/2021 - 06/2019
2	Proteins (Proteins, Gene)FDA Link 05/2021 - 04/2021
2	CytokinesIBA 04/2021 - 03/2015
2	Minocycline (Cyclops)FDA LinkGeneric 11/2020 - 10/2019
2	Betamethasone (Celestone)FDA Link 06/2018 - 12/2016
2	Clindamycin (Cleocin)FDA LinkGeneric 11/2017 - 09/2015
2	azelaic acid (Azelex)FDA Link 06/2016 - 11/2014
1	risankizumabIBA 06/2022
1	GelsIBA 01/2022
1	bimekizumabIBA 01/2022
1	Drug CombinationsIBA 01/2022
1	Clobetasol (Clobetasol Propionate)FDA LinkGeneric 01/2022
1	Pharmaceutical PreparationsIBA 06/2021
1	Acitretin FDA Link 05/2021
1	Retinoic Acid Receptors (Retinoic Acid Receptor)IBA 05/2021
1	Etretinate FDA Link 05/2021
1	Interleukin-17 (Interleukin 17)IBA 04/2021
1	LipidsIBA 04/2021
1	Transcription Factors (Transcription Factor)IBA 04/2021
1	LigandsIBA 04/2021
1	Phosphodiesterase 4 InhibitorsIBA 01/2020
1	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 01/2020
1	ClascoteroneIBA 01/2020
1	RoflumilastIBA 01/2020
1	CollagenIBA 03/2019
1	Doxycycline (Periostat)FDA LinkGeneric 03/2018
1	Biological ProductsIBA 02/2018
1	ingenolIBA 11/2017
1	LEO 43204IBA 11/2017
1	Metronidazole (Metric)FDA LinkGeneric 06/2016
1	EmollientsIBA 03/2016
1	diformyl dapsone (DFD)IBA 03/2016
1	Toll-Like Receptors (Toll-Like Receptor)IBA 03/2015
1	ChemokinesIBA 03/2015
1	tavaboroleIBA 03/2015
1	Proteinase-Activated ReceptorsIBA 03/2015
1	Desoximetasone (Topicort)FDA LinkGeneric 12/2013
1	3-ingenyl angelateIBA 06/2013
1	PeroxidesIBA 06/2013
1	Ustekinumab (CNTO 1275)FDA Link 01/2012
1	Tumor Necrosis Factor InhibitorsIBA 01/2012

Therapy/Procedure

31	Therapeutics 06/2022 - 01/2007
3	Aftercare (After-Treatment) 06/2022 - 11/2020
1	Phototherapy (Light Therapy) 01/2022
1	Retreatment 11/2019
1	Secondary Prevention 02/2012